Cell surface CD63 increased by up-regulated polylactosamine modification sensitizes human melanoma cells to the BRAF...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Melanoma treatment with BRAF inhibitor PLX4032 faces challenges due to acquired drug resistance.
• Melanoma-associated membrane glycoprotein CD63 plays a role in cell proliferation and metastasis.
• Developing strategies to overcome PLX4032 resistance in melanoma is critical.

Purpose of the Study:

• To investigate the role of cell surface CD63 in melanoma cell proliferation and response to PLX4032.
• To explore the potential of CD63 as a therapeutic target for drug-resistant melanoma.

Main Methods:

• Analysis of endogenous CD63 protein levels in relation to PLX4032 resistance in human melanoma cell lines.
• Overexpression of CD63 in melanoma cells with low endogenous levels.
• Investigating the effect of PLX4032 treatment on cell surface CD63 levels and polylactosamine modification.
• Assessing the impact of forced cell surface localization of CD63 on melanoma cell proliferation.

Main Results:

• Cell surface CD63 was found to suppress the proliferation of both parental and PLX4032-resistant human melanoma cells.
• Endogenous CD63 protein levels showed a negative correlation with PLX4032 resistance.
• PLX4032 treatment increased cell surface CD63 levels and molecular mass due to enhanced polylactosamine modification via upregulated β1,3- N-acetylglucosaminyltransferase 2.
• Overexpression or forced cell surface localization of CD63 reduced melanoma cell proliferation, even without PLX4032, and sensitized resistant cells.

Conclusions:

• Cell surface CD63, particularly when modified by polylactosamine, acts as a suppressor of melanoma cell proliferation.
• CD63 has the potential to sensitize melanoma cells to the BRAF inhibitor PLX4032.
• Targeting CD63 offers a promising strategy to reduce the proliferation of PLX4032-resistant melanoma cells.